Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases

Human Gene Therapy

Volumn 16, Issue 8, 2005, Pages 937-946

  Dow, Steven ^a   Elmslie, Robyn ^b   Kurzman, Ilene ^c   MacEwen, Gregory ^c   Pericle, Federica ^d   Liggitt, Denny ^e  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b Veterinary Referral Center of Colorado   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d Urigen Pharmaceuticals Inc   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (OLEOYLOXY)ETHYL] 2 OLEYL 3 (2 HYDROXYETHYL)IMIDAZOLINIUM CHLORIDE; CATION; CHLOROFORM; CHOLESTEROL; INTERLEUKIN 2; LIPID; LIPOSOME; PLASMID DNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CANCER STAGING; CLINICAL FEATURE; COMPLEX FORMATION; CONTROLLED STUDY; DOG; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; HEMATOLOGY; IMMUNE RESPONSE; LEUKOCYTE; LOW DRUG DOSE; LUNG METASTASIS; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; OSTEOSARCOMA; SURVIVAL TIME; TRANSGENE; TUMOR REGRESSION;

ANIMALS; BONE NEOPLASMS; DNA; DOG DISEASES; DOGS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE TRANSFER TECHNIQUES; INFUSIONS, INTRAVENOUS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LIPOSOMES; LUNG NEOPLASMS; NEOPLASM METASTASIS; OSTEOSARCOMA; PLASMIDS; SURVIVAL ANALYSIS; TRANSGENES;

ANIMALIA; CANIS FAMILIARIS;

EID: 23844478541     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.937     Document Type: Article

References (34)

1. ANWER, K., KAO, G., PROCTOR, B., ROLLAND, A., and SULLIVAN, S. (2000). Optimization of cationic lipid/DNA complexes for systemic gene transfer to tumor lesions. J. Drug Target. 8, 125-135.
2. BIANCO, S.R., SUN, J., FOSMIRE, S.P., HANCE, K., PADILLA, M.L., RITT, M.G., GETZY, D.M., DUKE, R.C., WITHROW, S.J., LANA, S., MATTHIESEN, D.T., DOW, S.W., BELLGRAU, D., CUTTER, G.R., HELFAND, S.C., and MODIANO. J.F. (2003). Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Ther. 10, 726-736.
3. BRAMSON, J.L., BODNER, C.A., and GRAHAM, R.W. (2000). Activation of host antitumoral responses by cationic lipid/DNA complexes. Cancer Gene Ther. 7, 353-359.
4. CLARK, P.R., STOPECK, A.T., FERRARI, M., PARKER, S.E., and HERSH, E.M. (2000). Studies of direct intratumoral gene transfer using cationic lipid-complexed plasmid DNA. Cancer Gene Ther. 7, 853-860.
5. DOW. S.W., ELMSLIE, R.E., WILLSON, A.P., ROCHE, L., GORMAN, C., and POTTER, T.A. (1998). In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J. Clin. Invest. 101, 2406-2414.
6. DOW, S.W., ELMSLIE, R.E., FRADKIN, L.G., LIGGITT, D.H., HEATH, T.D., WILLSON, A.P., and POTTER, T.A. (1999a). Intravenous cytokine gene delivery by lipid-DNA complexes controls the growth of established lung metastases. Hum. Gene Ther. 10, 2961-2972.
7. DOW, S.W., FRADKIN, L.G., LIGGITT, D.H., WILLSON, A.P., HEATH, T.D., and POTTER, T.A. (1999b). Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. I. Immunol. 163, 1552-1561.
8. FAIRMAN, I., ROCHE, L., PIESLAK, I., LAY, M., CORSON, S., FOX, E., LUONG, C., KOE, G., LEMOS, B., GROVE, R., FRADKIN, L., and VERNACHIO, I. (1999). Quantitative RT-PCR to evaluate in vivo expression of multiple transgenes using a common intron. Biotechniques 27, 566-570, 572-564.
9. HIGGINS, R.J., McKISIC, M., DICKINSON, P.J., JIMENEZ, D.F., DOW, S.W., TRIPP, L.D., and LECOUTEUR, R.A. (2004). Growth inhibition of an orthotopic glioblastoma in immunocompetent mice by cationic lipid-DNA complexes. Cancer Immunol. Immunother. 53, 338-344.
10. KAMSTOCK, D., GUTH, A., ELMSLIE, R., KURZMAN, I., LIGGITT, D., CORO L., FAIRMAN, I., and DOW. S. (2005). Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. Cancer Gene Ther. (in press).
11. KIRKNESS, E.F., BAFNA, V., HALPERN, A.L., LEVY, S., REMINGTON, K., RUSCH, D.B., DELCHER. A.L., POP, M., WANG, W., FRASER, C.M., and VENTER, J.C. (2003). The dog genome: Survey sequencing and comparative analysis. Science 301, 1898-1903.
12. KRASNICI, S., WERNER, A., EICHHORN, M.E., SCHMITT-SODY, M., PAHERNIK, S.A., SAUER, B., SCHULZE, B., TEIFEL, M., MICHAELIS, U., NAUJOKS, K., and DELLIAN, M. (2003). Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int. J. Cancer 105, 561-567.
13. LI, P.Y., LIN, I.S., FENG, Z.H., HE, Y.F., ZHOU, H.J., MA, X., CAI, X.K., and TIAN, D.A. (2004). Combined gene therapy of endostatin and interleukin 12 with polyvinylpyrrolidone induces a potent anti-tumor effect on hepatoma. World J. Gastroenterol. 10, 2195-2200.
14. LI, S., and HUANG, L. (1997). In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther. 4, 891-900.
15. LI, S., and MA, Z. (2001). Nonviral gene therapy. Curr. Gene Ther. 1, 201-226.
16. LIU, Y., MOUNKES, L.C., LIGGITT, H.D., BROWN, C.S., SOLODIN, I., HEATH, T.D., and DEBS, R.J. (1997). Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat. Biotechnol. 15, 167-173.
17. LIU, Y., THOR, A., SHTIVELMAN, E., CAO, Y., TU, G., HEATH, T.D., and DEBS, R.J. (1999). Systemic gene delivery expands the repertoire of effective antiangiogenic agents. J. Biol. Chem. 274, 13338-13344.
18. MACEWEN. E.G. (1990). Spontaneous tumors in dogs and cats: Models for the study of cancer biology and treatment. Cancer Metastasis Rev. 9, 125-136.
19. MISDORP, W. (1980). Skeletal osteosarcoma. Animal model: Canine osteosarcoma. Am. J. Pathol. 98, 285-288.
20. MIYATA, T., YAMAMOTO, S., SAKAMOTO, K., MORISHITA, R., and KANEDA, Y. (2001). Novel immunotherapy for peritoneal dissemination of murine colon cancer with macrophage inflammatory protein-1β mediated by a tumor-specific vector, HVJ cationic liposomes. Cancer Gene Ther. 8, 852-860.
21. NABEL, G.J., NABEL, E.G., YANG, Z.Y., FOX, B.A., PLAUTZ, G.E., GAO, X., HUANG, L., SHU, S., GORDON, D., and CHANG, A.E. (1993). Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. U.S.A. 90, 11307-11311.
22. NATSUME, A., TSUJIMURA, K., MIZUNO, M., TAKAHASHI, T., and YOSHIDA, I. (2000). IFN-β gene therapy induces systemic antitumor immunity against malignant glioma. J. Neurooncol. 47, 117-124.
23. NORMAN, J., DENHAM, W., DENHAM, D., YANG, J., CARTER, G., ABOUHAMZE, A., TANNAHILL, C.L., MACKAY, S.L., and MOLDAWER, L.L. (2000). Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation. Gene Ther. 7, 1425-1430.
24. PELFRENE, A.F. (1985). A search for a suitable animal model for bone tumors: A review. Drug Chem. Toxicol. 8, 83-99.
25. SAKURAI, F., TERADA, T., MARUYAMA, M., WATANABE. Y., YAMASHITA, F., TAKAKURA, Y., and HASHIDA, M. (2003). Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-β gene and poly(I):poly(C) in a murine lung metastasis model. Cancer Gene Ther. 10, 661-668.
26. SIDERS, W.M., VERGILLIS, K., JOHNSON, C., SCHEULE, R.K., and KAPLAN, J.M. (2002). Tumor treatment with complexes of cationic lipid and noncoding plasmid DNA results in the induction of cytotoxic T cells and systemic tumor elimination. Mol. Ther. 6, 519-527.
27. TEMPLETON, N.S., LASIC, D.D., FREDERIK, P.M., STREY, H.H., ROBERTS, D.D., and PAVLAKIS, G.N. (1997). Improved DNA:liposome complexes for increased systemic delivery and gene expression. Nat. Biotechnol. 15, 647-652.
28. THIERRY, A.R., RABINOVICH, P., PENG, B., MAHAN, L.C., BRYANT, J.L., and GALLO, R.C. (1997). Characterization of liposome-mediated gene delivery: expression, stability and pharmacokinetics of plasmid DNA. Gene Ther. 4, 226-237.
29. THURSTON, G., MCLEAN, J.W., RIZEN, M., BALUK, P., HASKELL, A., MURPHY, T.J., HANAHAN, D., and MCDONALD, D.M. (1998). Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Invest. 101, 1401-1413.
30. VAIL, D.M., and MACEWEN, E.G. (2000). Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest. 18, 781-792.
31. WHITMORE, M., LI, S., and HUANG, L. (1999). LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther. 6, 1867-1875.
32. WHITMORE, M.M., LI, S., FALO, L., Jr., and HUANG, L. (2001). Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol. Immunother. 50, 503-514.
33. WILSON, A., PITT, B., and LI, S. (2002). Complex roles of CpG in liposomal delivery of DNA and oligonucleotides. Biosci. Rep. 22, 309-322.
34. ZHOU, H.S., LIU, D.P., and LIANG, C.C. (2004). Challenges and strategies: The immune responses in gene therapy. Med. Res. Rev. 24, 748-761.